Evidence map›Paper›PMID 34545358›Full record

ArticleResearch square2021

Increased Neutrophil-Subset Associated With Severity/Mortality In ARDS And COVID19-ARDS Expresses The Dual Endothelin-1/VEGFsignal-Peptide Receptor (DEspR): An Actionable Therapeutic Target.

Victoria L M Herrera, Allan J Walkey, Mai Q Nguyen, Christopher M Gromisch, Julie Z Mosaddhegi, Matthew S Gromisch, Bakr Jundi, Soeren Lukassen, Saskia Carstensen, Ridiane Denis and 11 more

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 2 countries.

Victoria L M HerreraBoston University School of Medicine.
Allan J WalkeyBoston University School of Medicine.
Mai Q NguyenBoston University School of Medicine.
Christopher M GromischBoston University School of Medicine.
Julie Z MosaddhegiBoston University School of Medicine.
Matthew S GromischBoston University School of Medicine.
Bakr JundiBrigham and Women's Hospital, Harvard Medical School.
Soeren LukassenBerlin Institute of Health and Charité - Universitätsmedizin Berlin, Universität Berlin, Humboldt-Universität zu Berlin.
Saskia CarstensenFraunhofer Institute for Toxicology and Experimental Medicine.
Ridiane DenisBoston University School of Medicine.
Anna C BelkinaBoston University School of Medicine.
Rebecca M BaronBrigham and Women's Hospital, Harvard Medical School.
Mayra Pinilla-VeraBrigham and Women's Hospital, Harvard Medical School.
Meike MullerFraunhofer Institute for Toxicology and Experimental Medicine.
W Taylor KimberlyMassachusetts General Hospital, Harvard Medical School.
Joshua N GoldsteinMassachusetts General Hospital, Harvard Medical School.
Irina LehmannCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health (BIH).
Angela R ShihMassachusetts General Hospital, Harvard Medical School.
Roland EllsBerlin Institute of Health and Charité - Universitätsmedizin Berlin, Universität Berlin, Humboldt-Universität zu Berlin.
Bruce D LevyBrigham and Women's Hospital, Harvard Medical School.
Nelson Rulz-OpazoBoston University School of Medicine.
Boston University · USBrigham and Women's Hospital · USFraunhofer Institute for Toxicology and Experimental Medicine · DEHarvard University · USHumboldt-Universität zu Berlin · DE

Funding

Project-005UL1TR001430 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BAIR-MERRITT, MEGAN H, CENTER, DAVID M. · 2015 to 2024
$52.3M
Boston Biomedical Innovation CenterU54HL119145 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GOLAN, DAVID E., LOSCALZO, JOSEPH · 2013 to 2021
$18.8M
Therapeutic modulation of zinc for lung injury and mechanobiologyR01HL142093 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BARON, REBECCA M, TSCHUMPERLIN, DANIEL J. · 2019 to 2022
$2.8M
NCATS NIH HHS UL1 TR001430NHLBI NIH HHS U54 HL119145
6 · The paper itself

Abstract

Neutrophil-mediated secondary tissue injury underlies acute respiratory distress syndrome (ARDS) and progression to multi-organ-failure (MOF) and death, processes linked to severe COVID19. This 'innocent bystander' tissue injury arises in dysregulated hyperinflammatory states from neutrophil functions and neutrophil extracellular traps (NETs) intended to kill pathogens, but injure cells instead, causing MOF. Insufficiency of prior therapeutic approaches suggest need to identify dysregulated neutrophil-subset(s) and induce subset-specific apoptosis critical for neutrophil function-shutdown and clearance. We hypothesized that neutrophils expressing the pro-survival dual endothelin-1/signal peptide receptor, DEspR, are apoptosis-resistant just like DEspR+ cancer cells, hence comprise a consequential pathogenic neutrophil-subset in ARDS and COVID19-ARDS. Here, we report correlation of circulating DEspR+CD11b+ activated neutrophils (DESpR+actNs) and NETosing-neutrophils with severity in ARDS and in COVID19-ARDS, increased DEspR+ neutrophils and monocytes in post-mortem ARDS-patient lung sections, and neutrophil DEspR/ET1 receptor/ligand autocrine loops in severe COVID19. Unlike DEspR[-] neutrophils, ARDS patient DEspR+actNs exhibit apoptosis-resistance, which decreased upon

Indexed as

ARDSCOVID19-ARDSDEspRneutrophil subsetsecondary tissue injury

Identifiers

PMID34545358
PMCPMC8452107
OpenAlexW3200854080

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.